| Literature DB >> 29572075 |
Joseph M Unger1, Riha Vaidya2, John L Gore3.
Abstract
Advances in early detection and therapy have increased the number of prostate cancer survivors, leading to a greater emphasis on examining patient-reported outcomes (PROs). PROs augment clinical outcomes, providing a more comprehensive assessment of the patient experience, including symptoms and quality of life, that may impact the overall evaluation of new therapies. The successful incorporation of PROs into clinical trials requires adherence to key design and analysis principles. We present these principles and argue that adherence to these principles is vital to ensure valid interpretation of clinical trial findings, identify meaningful differences among investigational strategies, and better translate clinical trial results to diverse stakeholders.Entities:
Keywords: Patient-reported outcomes; Prostate cancer; Quality of life
Mesh:
Year: 2018 PMID: 29572075 PMCID: PMC6148417 DOI: 10.1016/j.urolonc.2018.02.012
Source DB: PubMed Journal: Urol Oncol ISSN: 1078-1439 Impact factor: 3.498